Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befizal for Leber Hereditary Optic Neuropathy
NCT04561466Phase 3Completed
- Sponsor
- Hôpital Necker-Enfants malades
- Start
- Mar 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bezafibrate in Leber hereditary optic neuropathy (LHON), sponsored by Hôpital Necker-Enfants malades. Primary endpoint: Best Corrected Farsight Visual Acuity at Month 12. Started Mar 2019; status: completed.
02
Drugs
bezafibrate
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT04561466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561466.